Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

This Dividend Stock Yields Nearly 8% and Trades at Depressed Valuations: Time to Buy?

Amid the continued decline in Pfizer stock, its dividend yield has risen to almost 8%. While the stock might not be a screaming buy, it now seems to have limited downside.

Barchart

Zimmer Biomet Hits 34th 52-Week Low: Value Play or Value Trap?

Zimmer Biomet hit its 34th 52-week low on Tuesday. Its shares have decreased by over 20% in the past year. Trading at just 11.8x the 2025 EPS estimate, the maker of orthopedic medical devices looks cheap.

Barchart

Pfizer will end development of weight-loss pill over fears about its impact to the liver

The drugmaker said the patient’s injury ‘resolved’ after they stopped taking the drug

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer stops working on potential pill to treat obesity after study participant has liver injury

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury.

Euronews

Trump Tariffs Unnerve Locals In Irish 'Pharma' Hub

Vast pharmaceutical factories pepper the green landscape in southern Ireland, but the wind turbines next to the plants outside Cork are in the eye of Donald Trump's global trade storm.

International Business Times

3 Unusally Active Long-Haul Call Options to Buy From Wednesday’s Wild Ride

Yesterday’s S&P 500 move from 4,950 to 5,456.90 at the close was one for the ages. The 90-day pause lit a fire under investors. These three unusually active long-haul call options stood out.

Barchart

Huge Unusual Trading in Pfizer Put Options Signals Investors' Bearish Outlook

Large, unusual trading volume in Pfizer put options is accruing today, signaling a bearish outlook by institutional investors in PFE stock. This undoubtedly relates to the Chinese tariffs, and investors' concerns.

Barchart

Read news from The Economist, FT, and more,
with one subscription

‘Half the place would be blown to bits’: the Irish villages under threat from Trump’s tariffs

Cork’s pharmaceutical industry, vital to the local economy, is at risk as US trade policies threaten small towns reliant on the sector

The Guardian - UK

Trump tariffs could soften one of Europe’s most expensive housing markets—if tech workers face layoffs

Tech and pharma employees in Ireland are at risk from an escalating Trump trade war.

Fortune

Did pharma sector dodge Trump’s tariffs? The EU's not so sure

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

Euronews

Analysts at Trump ally Howard Lutnick’s former firm call RFK Jr. ‘an anti-vax, conspiracy theorist with inadequate training’

RFK Jr. was reportedly behind the ouster of FDA’s top vaccine official and said last week that around 10,000 employees will be laid off at the Department of Health and Human Services.

Fortune

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

MarketBeat

Tariff treatment: Six diagnoses for EU pharma sector amid US trade war

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

Euronews

Pfizer offloads final shares in Sensodyne maker Haleon

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Reason

Are COVID-19 Vaccines Safe and Effective?

Five years after Donald Trump declared a national COVID-19 emergency, here's what the research says.

The Conversation

Treatment for Parkinson’s disease and restless leg syndrome is linked with risky behaviour – here’s what you need to know

Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behaviour or pathological gambling – not so common.

Barchart

How Is Pfizer's Stock Performance Compared to Other Pharmaceuticals Stocks?

Pfizer has underperformed the pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

StockNews.com

3 Gene Therapy Stocks With Game-Changing Potential

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, investing in gene therapy stocks like Pfizer (PFE), Sanofi (SNY), and Novartis AG (NVS) could be beneficial. Read on….

Get all your
news in one place.

100’s of premium titles.
One news app.

Latin Times

Pfizer Exec Booed During White House Appearance as Trump Calls Pharma Head 'Great Businessman'

President Donald Trump's introduction of a Pfizer executive at the White House Wednesday was met with a roar of boos from the crowd.

Top News

Pfizer CEO Booed At White House Event

President Trump's praise of Pfizer CEO at Black History Month event sparks mixed audience reactions due to company's Covid-19 vaccine controversy.

Barchart

Is This Dividend Stock a Buy After Better-Than-Expected Q4 Results?

Upcoming clinical trial results will give investors a much better look into Pfizer’s operational health.

Sports Illustrated

Joe Montana On Brock Purdy's Future, Notre Dame, and 49ers' Window

Football legend Joe Montana joins SI's Claudette Montana, on behalf of Pfizer, to discuss Brock Purdy's future in San Francisco, Marcus Freeman and Notre Dame,

International Business Times

Pfizer's Super Bowl 2025 Ad Featuring Young Cancer Survivor Sparks Mixed Reactions

Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will "knock out" cancer amid concerns over its COVID-19 vaccine.

Fortune

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

The Independent UK

Robert F. Kennedy had dinner with Pfizer CEO as he prepares to become health secretary, report says

Pfizer CEO certain that Trump’s administration ‘will be very, very prudent with everything they try to do’

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.